Undesirable β2-AR agonist effects such as elevation of HR and arrhythmia risk shown by certain studies [41], [42], along with fears over increasing LV mass, both independent prognostic risk factors in cardiac disease [43], [44] tempered enthusiasm for using β2-AR agonists in HF therapy. This evidence concerns the gene ADRB2 and heart disorder.